Jubilant Organosys sells $200 million CB while pondering possible acquisition

Issue marks seventh CB from an Indian pharmaceutical company since December; conversion premiums still high.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES